Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma: The CANIQOL Multicentre Study

NCT07028125 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT07028125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07028125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma: The CANIQOL Multicentre Study
Lead sponsor
Centre Francois Baclesse
Phase
Phase 4
Overall status
Recruiting
Start date
October 1, 2025
Completion date
January 31, 2029
Enrollment
83 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced, metastatic renal cell carcinoma, renal cell carcinoma (kidney cancer)